Randomised controlled trial of nicotine chewing-gum

Area of Science:

• Addiction Medicine
• Pharmacology
• Behavioral Science

Background:

• Smoking cessation remains a significant public health challenge.
• Nicotine dependence is a primary driver of continued smoking behavior.
• Pharmacological aids are crucial for supporting individuals attempting to quit smoking.

Purpose of the Study:

• To evaluate the efficacy of 2 mg nicotine chewing gum as a smoking cessation aid.
• To compare nicotine gum against a placebo in a double-blind, randomized trial.
• To assess the impact of nicotine gum on withdrawal symptoms and long-term smoking abstinence.

Main Methods:

• A double-blind, randomized controlled trial was conducted.
• Participants were assigned to receive either 2 mg nicotine chewing gum or a placebo gum.
• Smoking status was assessed at one-year follow-up, along with withdrawal symptom severity and gum usage patterns.

Main Results:

• 47% of subjects using nicotine gum achieved one-year abstinence versus 21% using placebo (p<0.025).
• Nicotine gum users reported less severe withdrawal symptoms and found the gum more helpful.
• Lower pretreatment blood nicotine levels predicted greater success in quitting.

Conclusions:

• Nicotine chewing gum is an effective aid for smoking cessation.
• Nicotine plays a critical role in cigarette dependence and withdrawal symptom management.
• Optimal use of nicotine gum requires managing user expectations and providing clear instructions.